

CHARACTERISTICS OF INHIBITORS IN PATIENTS WITH HEMOPHILIA IN NATIONAL INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION, HA NOI, VIET NAM

Nguyen Thi Mai, Nguyen Thi Nu, Nguyen Anh Tri, Bach Quoc Khanh
National Institute of Hematology and Blood Transfusion, Hanoi, Vietnam
hemophiliavn@gmail.com – hemoviet.org.vn



OBJECTIVES

The Hemophilia Center in National Institute of Hematology and Blood Transfusion is the largest center in Vietnam. A study on 1,000 patients with hemophilia were examined to determine prevalence and severity of inhibitor development.

METHODS

All patients were screened for inhibitors, using the mix test. These were carried out at diagnosis, regularly every 3 months, when clinical signs of poor response to treatment or before each surgery. As mix test depends on time and temperature, patients were quantified using the Bethesda method.

RESULTS

The results showed that there were 56 patients with inhibitors with a prevalence of 5.6%, in which all patients were hemophilia A. There was no patient with hemophilia B. The majority of patients with inhibitors were severe (50; 89.28 %), 3 patients were mild (5;36%) and 3 patients were moderate (5;36%). There were 5 patients with inhibitors that were related to surgery, including 2 patients with moderate. Among severe patients, there were 10 people have intron 22 inversions with ratio 25.64 %. Inhibitor titer ranged from 1-72 BU. There were 15 patients (26.29%) with low titer inhibitor and 41 patients (73.21 %) with high titer inhibitors. Number of patients with transient inhibitors were 15 while the remaining (41 patients) with persistent inhibitors.

CONCLUSIONS

In the absence of bypass agents, the control of bleeding for this patients have many difficulties. There were two patients died due to bleeding.

REFERENCES

1. Nu N.T, Mai N.T (2011), Preliminary study on inhibitor FVIII/IX in patient with hemophilia in NIHBT, Vietnam Medical J, Vol 318, 107-112
2. [Christine L. Kempton](#) and [Gilbert C. White II](#), 2009, How we treat a hemophilia A patient with a factor VIII inhibitor, Blood January 1, 2009 vol. 113, no. 1, 11-17
3. Peter W. Collins, Elizabeth Chalmers, Daniel P. Hart, Ri Liesner, Savita Rangarajan, Kate Talks, Mike Williams and Charles R. Hay, (2013), Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia (4th edition), British Journal of Haematology, 2013, 160, 153–170.

Bleeding after intramuscular injection in a patient with hemophilia A with high titer inhibitor

